Absence of constitutive EGF receptor activation in ovarian cancer cell lines

British Journal of Cancer

Volumn 74, Issue 3, 1996, Pages 446-452

  Ottensmeier, C ^a,b   Swanson, L ^a,b   Strobel, T ^a,b   Druker, B ^c   Niloff, J ^d   Cannistra, S A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Epidermal growth factors receptor; Ovarian cancer; Tyrosine phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; RECEPTOR ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL DENSITY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0030016729     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.379     Document Type: Article

References (29)

1. BAST RC Jr, JACOBS I AND BERCHUCK A. (1992). Malignant transformation of ovarian epithelium. J. Natl Cancer Inst., 52, 5322-5328.
2. BERCHUCK A, RODRIGUEZ GC, KAMEL A, DODGE RK, SOPER JT, CLARKE-PEARSON DL AND BAST RC Jr. (1991). Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol., 164, 669-674.
3. CANNISTRA SA. (1993). Cancer of the ovary. N. Engl. J. Med., 329, 1550-1559.
4. CANNISTRA SA, KANSAS GS, NILOFF J, DEFRANZO B, KIM Y AND OTTENSMEIER C. (1993). Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res., 53, 3830-3838.
5. CARPENTER G AND COHEN S. (1990). Epidermal growth factor. J. Biol. Chem., 265, 7709-7712.
6. CREW AJ, LANGDON SP, MILLER EP AND MILLER WR. (1992). Mitogenic effects of epidermal growth factor and transforming growth factor-alpha on EGF-receptor positive human ovarian cancer cell lines. Eur. J. Cancer, 28, 337-341.
7. DI FIORE PP, PIERCE JH, KRAUS MH, SEGATTO O, KING CR AND AARONSON SA. (1987). erB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178-182.
8. DI MARCO E, PIERCE JH, FLEMING TP, KRAUS MH, MOLLOY CJ, AARONSON SA, AND DIFIORE PP. (1989). Autocrine intereaction between TGF-a and the EGF receptor: Quantitative requirements for induction of the malignant phenotype. Oncogene, 4, 831 838.
9. GULLI LF, KIM HR, PALMER K AND REDDY KB. (1995). Apoptosis induced by the epidermal growth factor is rescued by tyrosine kinase inhibitor in A431 cells. Proc. Am. Assoc. Cancer Res., 36, 10.
10. HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad. Sci. USA, 84, 7159-7163.
11. KANAKURA Y, DRUKER B, CANNISTRA SA, FURUKAWA Y, TORIMOTO Y AND GRIFFIN JD. (1990). Signal transduction of the human granulocyte-macrophase colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood, 76, 706-715.
12. KEATING MT AND WILLIAMS LT. (1988). Autocrine stimulation of intracellular PDGF receptors in v-sis-transformed cells. Science, 239, 914-916.
13. KHAZAIE K, DULI TJ, GRAF T, SCHLESSINGER J, ULLRICH A, BEUG H AND VEENSTROM B. (1988). Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts. EMBO J., 7, 3061-3071.
14. KUPRYJANCZYK V, THOR AD, BEAUCHAMP R, MERRITT V, EDGERTON SM, BELL DA AND YANDELL DW. (1993). p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Nail Acad. Sci. USA, 90, 4961-4965.
15. MILLS GB, MAY C, MCGILL M, ROIFMAN CM AND MELLORS A (1988). A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res., 48, 1066-1071.
16. MILLS GB, MAY C, HILL M, CAMPBELL S, SHAW P AND MARKS A (1990). Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J. Clin. Invest., 86, 851-855.
17. MILNER BJ, ALLAN LA, ECCLES DM, KITCHENER HC, LEONARD RCF, KELLY KF, PARKIN DE AND HAITES NE. (1993). p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res., 53, 2128-2132.
18. MORISHIGE K, KURACHI H, AMEMIYA K, FUJITA Y, YAMAMOTO T, MIYAKE A AND TANIZAWA O. (1993). Evidence for the involvement of transforming growth factor-α epidermal growth factor receptor autocrine growth mechanism in primary ovarian cancers. Cancer Res., 51, 5322-5328.
19. MOSMANN T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
20. PELICCI G, LANFRANCONE L, GRIGNANI F, MCGLADE J, CAVALLO F, FORNI G, NICOLETTI I, GRIGNANI F, PAWSON T AND PELICCI PG. (1992). A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell, 70, 93-104.
21. RODRIGUEZ GC, BERCHUCK A, WHITAKER RS, SCHLOSSMAN D, CLARKE-PEARSON DL AND BAST RC Jr. (1991). Epidermal growth factor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am. J. Obstet. Gynecol., 164, 745-750.
22. SCAMBIA G, PANICI PB, BATTAGLIA F, FERRANDINA G, BAIOCCHI G, GREGGI S, DEVINCENZO R AND MANCUSO S (1992). Significance of epidermal growth factor receptor in advanced ovarian cancer. J. Clin. Oncol., 10, 529-535.
23. SLAMON DJ, GODOLPHIN W, JONES LA, HOLT JA, WONG SG, KEITH DE, LEVIN WJ, STUART SG, UDOVE J, ULLRICH A AND PRESS MF. (1989). Studies of the HER/2-neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712.
24. STROMBERG K, COLLINS TJ, GORDON AW, JACKSON CL AND JOHNSON GR. (1992). Transforming growth factor-α acts as an autocrine growth factor in ovarian carcinoma cell lines. Cancer Res., 52, 341-347.
25. TENERIELLO MG, EBINA M, LINNOILA RI, HENRY M, NASH JD. PARK RC AND BIRRER MJ. (1993). p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res., 53, 3103-3108.
26. ULLRICH A AND SCHLESSINGER J. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203-212.
27. VAN DE VIJVER MJ, KUMAR R AND MENDELSOHN J. (1991). Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J. Biol. Chem., 266, 7503-7508.
28. WU J, ROSSOMANDO AJ, HER J-H, DEL VECCHIO R, WEBER MJ AND STURGILL TW. (1991). Autophosphorylation in vitro of recombinant 42-kilodalton mitogen-activated protein kinase on tyrosine. Proc. Natl Acad. Sci. USA, 88, 9508-9512.
29. ZHOU LI AND LEUNG BS. (1992). Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors-alpha and beta-1. Biochim. Biophys. Acta, 1080, 130-136.